Get the Stockscreener App
4.95
2.56%
-0.13
After Hours:
5.00
0.05
+1.01%
Rxsight Inc stock is traded at $4.95, with a volume of 690.16K.
It is down -2.56% in the last 24 hours and up +7.61% over the past month.
RxSight Inc is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture, and sale of light adjustable lenses and related capital equipment.
See More
Previous Close:
$5.08
Open:
$5.08
24h Volume:
690.16K
Relative Volume:
0.68
Market Cap:
$204.91M
Revenue:
$134.48M
Net Income/Loss:
$-38.94M
P/E Ratio:
-5.1919
EPS:
-0.9534
Net Cash Flow:
$-19.34M
1W Performance:
-11.76%
1M Performance:
+7.61%
6M Performance:
-44.00%
1Y Performance:
-41.49%
1-Day Range:
$4.875
$5.11
1-Week Range:
$4.805
$5.90
52-Week Range:
$4.48
$13.22
Rxsight Inc Stock (RXST) Company Profile
Name
Rxsight Inc
Sector
Industry
Phone
949-521-7822
Address
100 COLUMBIA STREET, ALISO VIEJO
Compare RXST vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RXST
Rxsight Inc
|
4.95 | 204.91M | 134.48M | -38.94M | -19.34M | -0.9534 |
ABT
Abbott Laboratories
|
93.93 | 163.61B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
329.78 | 126.42B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
83.87 | 107.36B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
44.77 | 66.54B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
92.21 | 53.09B | 6.30B | 1.07B | 1.09B | 1.8406 |
Rxsight Inc Stock (RXST) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Initiated | William Blair | Mkt Perform |
| Jul-15-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-10-25 | Downgrade | Jefferies | Buy → Hold |
| Jul-09-25 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-09-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-09-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-19-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-15-25 | Initiated | Piper Sandler | Neutral |
| Apr-09-25 | Downgrade | UBS | Buy → Neutral |
| Apr-04-25 | Downgrade | JP Morgan | Overweight → Underweight |
| Apr-03-25 | Downgrade | BofA Securities | Buy → Underperform |
| Dec-20-24 | Downgrade | Stifel | Buy → Hold |
| Dec-11-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-06-24 | Initiated | UBS | Buy |
| Oct-29-24 | Initiated | Jefferies | Buy |
| Aug-20-24 | Reiterated | Needham | Buy |
| Aug-06-24 | Reiterated | Needham | Buy |
| May-07-24 | Reiterated | BTIG Research | Buy |
| Dec-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-12-23 | Initiated | Stifel | Buy |
| Dec-04-23 | Initiated | Morgan Stanley | Overweight |
| Apr-13-23 | Initiated | Oppenheimer | Outperform |
| Dec-12-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-08-22 | Initiated | Needham | Buy |
View All
Rxsight Inc Stock (RXST) Latest News
Alcon, RxSight announce collaboration to develop adjustable presbyopia-correcting IOLs - Ophthalmology Times Europe
RxSight Q2 sales sink 20% as Alcon deal bolsters 2026 outlook - MSN
RxSight Q2 Sales Sink 20% as Alcon Deal Bolsters 2026 Outlook - Yahoo Finance
RxSight (RXST) Faces Investigation Over Board's Fiduciary Duties - GuruFocus
RxSight: After Dropping To The Bottom, It's Time To Pick It Up (NASDAQ:RXST) - Seeking Alpha
Glancy Prongay Wolke & Rotter LLP Announces Investigation of RxSight, Inc. (RXST) on Behalf of Investors - The AI Journal
(RXST) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Midday Stock Roundup: Alignment Healthcare Up 7.8% Ahead of Q2 Results - Orange County Business Journal
Alcon collaborates with RxSight to develop adjustable PCIOLs - MSN
Is Alcon (SWX:ALC) Cheap Following Its RxSight Collaboration And Premium P E? - simplywall.st
Is Alcon (SWX:ALC) Undervalued After Its RxSight Collaboration? - Yahoo Finance
Law Offices of Howard G. Smith Announces Investigation of RxSight, Inc. (RXST) on Behalf of Investors - FinancialContent
Can Alcon Inc. (ALC) Stock Rebound as New Eye Care Products Approach Regulatory Milestones? - Insider Monkey
RxSight: Alcon Deal Reshapes The Long-Term Growth Story (NASDAQ:RXST) - Seeking Alpha
Alcon and RxSight Announce Collaboration to Develop Adjustable PCIOLs - InvisionMag.com
Price to book forward of RxSight, Inc. – NASDAQ:RXST - TradingView
RxSight, Inc. Reports Preliminary Financial Results for the Second Quarter of 2026 - VisionMonday.com
Price to sales forward of RxSight, Inc. – NASDAQ:RXST - TradingView
Alcon and RxSight partner to to develop light-adjustable PCIOLs - Eyes On Eyecare
ALC News & Events - Intellectia AI
Enterprise value to EBIT forward of RxSight, Inc. – NASDAQ:RXST - TradingView
RxSight (RXST) Adjusts FY26 Revenue Forecast Amid Collaboration Insights - GuruFocus
The Law Offices of Frank R. Cruz Announces Investigation of RxSight, Inc. (RXST) on Behalf of Investors - Business Wire
RXST Maintained by B of A Securities -- Price Target Lowered to $6.50 - GuruFocus
BofA cuts RxSight stock price target on weak Q2 sales, guidance - Investing.com Nigeria
BofA cuts RxSight stock price target on weak Q2 sales, guidance By Investing.com - Investing.com South Africa
RxSight Announces Preliminary Q2 Results - Orange County Business Journal
RxSight Inc. (RXST) PT Lowered to $6.50 at BofA Securities - StreetInsider
RxSight, Inc. Provides Preliminary Revenue Guidance for the Second Quarter Ended June 30, 2026 - marketscreener.com
RxSight stock tumbles on reduced 2026 sales guidance By Investing.com - Investing.com South Africa
Alcon, RxSight Begin Co-Developing Presbyopia-Correcting IOLs - Medical Product Outsourcing
Stifel reiterates Hold on RxSight stock, $8 target on Alcon deal By Investing.com - Investing.com South Africa
Stifel reiterates Hold on RxSight stock, $8 target on Alcon deal - Investing.com
Rxsight Q2 Revenue USD 27 Million Vs. IBES Es - Moomoo
Alcon spends up to $200m to co-develop customisable cataract lenses with RxSight - Yahoo Finance
RxSight reports preliminary Q2 revenue, revises 2026 guidance - MSN
RxSight (RXST) Reiterated at Hold by Stifel as ALC Collaboration Announced - StreetInsider
Rivian Automotive, Penguin Solutions And 3 Stocks To Watch Heading Into Tuesday - Benzinga
RXST: 2026 revenue guidance lowered, gross margin raised, and next-gen lens pipeline advances - TradingView
Alcon, RxSight Partner to Develop Adjustable Presbyopia-Correcting IOLs - VisionMonday.com
RxSight raises FY26 sales guidance to $140M-$160M - scanx.trade
Alcon, RxSight partner on adjustable lens technology - Investing.com UK
Alcon, RxSight partner on adjustable lens technology By Investing.com - Investing.com South Africa
Alcon (ALC) Partners with RxSight for Innovative Lens Developmen - GuruFocus
RxSight reports Q2 revenue of $32-34M, cuts 2026 sales outlook - Investing.com
ALCON AGRXSIGHT TO RECEIVE $60 MLN UPFRONT PAYMENT UNDER AGREEMENT - Moomoo
RxSight says Q2 results hit by more widespread competitive trialing - TradingView
RxSight cuts 2026 sales outlook, citing competitive headwinds - StreetInsider
RxSight (NASDAQ: RXST) cuts 2026 sales outlook but lifts margin view - Stock Titan
Rxsight, Inc. Updates Revenue Guidance for the Full Year 2026 - marketscreener.com
Join Class Action to Recover Losses From RxSight, Inc. (RXST)Contact Levi & Korsinsky Before September 22, 2025 - The National Law Review
Rxsight Inc Stock (RXST) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):